Chemotherapy plus Immunotherapy before Surgery for High-Risk Colon Cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of two chemotherapy drugs (CAPOX) plus an immunotherapy drug (tislelizumab) before surgery for high-risk colon cancer that has not spread. It aims to see if adding tislelizumab helps shrink the tumor and lower the chance of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your colon cancer must be confirmed as MSS (not MSI-high) — this means the tumor cells do not have a specific DNA repair defect.
- The tumor must be in the upper part of the colon (at least 12 cm from the anus) and be at a high risk of coming back.
- You must not have had any prior cancer treatment and must be able to undergo chemotherapy.
- You must be in generally good health (able to do daily activities) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies giving chemotherapy plus immune therapy before surgery for certain colon cancers that do not have mismatch repair defects (MSS/pMMR). The goal is to shrink and control the tumor and improve outcomes compared with standard approaches.
This trial tests whether giving chemotherapy followed by an immunotherapy drug (a checkpoint inhibitor) before surgery helps shrink locally advanced colon cancer. It is for people with a specific tumor type (MSS and RAS mutation) who have not had prior treatment.
This trial tests immunotherapy plus chemotherapy given before surgery for colon cancer that hasn’t spread. It aims to shrink or control the tumor and improve outcomes in people whose tumor has certain immune/biologic features.
This trial tests a combination of an immunotherapy drug (PD-1 antibody), two types of immune-boosting drugs (rhG-CSF and IL-2), and chemotherapy (CapeOX) given before surgery for colorectal cancer that has spread to the liver. The goal is to see if this combination can shrink tumors and improve outcomes, and it is designed for patients whose cancer can be surgically removed.
This trial tests whether adding immunotherapy (a treatment that helps your immune system fight cancer) to standard chemotherapy before surgery works better than chemotherapy alone for people with locally advanced colorectal cancer.
This trial tests whether giving an immunotherapy drug (tislelizumab) together with chemotherapy before and after surgery can improve outcomes for people with a specific type of colorectal cancer (MSI-high). The goal is to see if this treatment helps shrink the tumor and reduces the risk of cancer coming back.
Hear when a new Colonic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.